Position
Director
Company
Xeris Biopharma Holdings
ChicagoBiotechnologyHealthcareHealth CareBiopharmaDescription
Xeris Biopharma Holdings, Inc. appointed Menassie Taddese as a Class II director effective November 2, 2026. The appointment increases the Board size from eight to nine members, filling a newly created vacancy
Quick answer
Menassie Taddese Appointed as Director at Xeris Biopharma (November 2, 2026). Xeris Biopharma Holdings is based in Chicago, Illinois, United States.
- Who is the new Director at Xeris Biopharma Holdings?
- Xeris Biopharma Holdings named Menassie Taddese Director, announced November 2, 2026.
- What did Xeris Biopharma Holdings announce on November 2, 2026?
- Xeris Biopharma Holdings, Inc. appointed Menassie Taddese as a Class II director effective November 2, 2026.
- What does Xeris Biopharma Holdings do?
- Xeris Biopharma Holdings, Inc. is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies.
- Where is Xeris Biopharma Holdings based?
- Xeris Biopharma Holdings is based in Chicago, Illinois, United States.
- Which similar companies made leadership changes around the same time?
- AbbVie Inc. (November 2, 2026), Tempest Therapeutics (November 4, 2026), Retension Pharmaceuticals (October 23, 2026) and Gyre Therapeutics (October 22, 2026) also announced leadership changes within 45 days of Xeris Biopharma Holdings.
Source: Fundz verified event record.
Other recent leadership changes in Healthcare and Biopharma
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- AbbVie Director Resigns Following CEO Appointment at Align Technology (November 2, 2026)
- Tempest Therapeutics names Stephanie Horn-Warnock CFO, Treasurer, & Corp Sec. (November 4, 2026)
- Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer (October 23, 2026)
- Gyre Therapeutics Appoints Ying Luo as CEO and Thomas Eastling as CFO (October 22, 2026)
- Verastem Oncology Appoints Michael P. Bailey as Chief Executive Officer (October 14, 2026)
- OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer (October 1, 2026)
Who to call at Xeris Biopharma Holdings, and when
A new leader at Xeris Biopharma Holdings brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Xeris Biopharma Holdings raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Xeris Biopharma Holdings, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Xeris Biopharma Holdings. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Xeris Biopharma Holdings changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Xeris Biopharma Holdings changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.